, aspects : préparation des échantillons, types de cytomètres, choix des panels d'anticorps utilisés, seuils de quantification, stratégie d'analyse. L'innovation et la complexité croissantes des cytomètres avec l'analyse possible en 10 couleurs (bientôt 13 couleurs) et la diversité des réactifs disponibles rendent nécessaire la définition de stratégies pour aboutir à une bonne reproductibilité inter-laboratoires

, Ainsi il existe déjà un certain nombre d'études ayant réalisé des essais multicentriques dans le but de standardiser l'analyse (75) (76) (77). Ces études confirment la capacité à obtenir des résultats satisfaisants en termes de sensibilité et reproductibilité

, En France le Groupe d'Etude Immunologique des Leucémies (GEIL) travaille sur

, harmonisation des centres Français à travers les réglages et le suivi des performances des cytomètres avec notamment des procédures concernant le passage des billes Flow-Set Pro pour une standardisation des systèmes

, Il travaille sur la standardisation des paramétrages des automates de cytométrie, la préparation des échantillons, les procédures d'immunomarquage, ainsi que l'analyse automatisée des données. L'équipe de Theunissen et al en collaboration avec Euroflow a réalisé une étude en deux phases, Le consortium EuroFlow est un réseau européen crée dans le but d'optimiser et standardiser les analyses en CMF

M. F. Fey, Normal and malignant hematopoiesis, Ann Oncol Off J Eur Soc Med Oncol. janv, vol.18, 2007.

A. Fernandes and . Hématopoïèse-knoow,

H. W. Schroeder and L. Cavacini, Structure and Function of Immunoglobulins, J Allergy Clin Immunol. févr, vol.125, issue.2 0 2, pp.41-52, 2010.

M. Ruiz, IMGT, the international ImMunoGeneTics database, Nucleic Acids Res. 1 janv, vol.28, issue.1, pp.219-240, 2000.

D. Rizzo, Étude des paramètres biologiques influençant l'histoire naturelle de la leucémie lymphoïde chronique : expression du CD45, sécrétion d'une IgM monoclonale et dérégulation de ZAP70

. Limoges, , 2014.

J. H. Michael and . Ratcliffe, Encyclopedia of Immunobiology, 2016.

S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol.2

M. S. Linet, L. A. Ries, M. A. Smith, R. E. Tarone, and S. S. Devesa, Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States, J Natl Cancer Inst. 16 juin, vol.91, issue.12, pp.1051-1059, 1999.

A. Monnereau, L. Remontet, M. Maynadié, F. Binder-foucard, A. Belot et al., Estimation nationale de l'incidence des cancers en France entre, 1980.

L. Brigitte, D. Emmanuel, and G. Sandra, Registre national des tumeurs solides de l'enfant

C. Sermage-faure, Incidence des leucémies de l'enfant en fonction de la proximité et des caractéristiques générales de diverses sources d'expositions environnementales

M. Maynadié and X. Troussard, Épidémiologie des leucémies aiguës. /data/revues/1773035X/v2015i471/S1773035X1530071X, 2015.

. Disponible,

C. A. Stiller, Epidemiology and genetics of childhood cancer, Oncogene. 23 août, vol.23, issue.38, pp.6429-6473, 2004.

C. P. Dame and . Hematology, Third Edition, pp.548-61, 2007.

L. Levato and S. Molica, Rituximab in the management of acute lymphoblastic leukemia, Expert Opin Biol Ther. févr, vol.18, issue.2, pp.221-227, 2018.

M. Cernan, T. Szotkowski, and Z. Pikalova, Mixed-phenotype acute leukemia: state-of-the-art of the diagnosis, classification and treatment, Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov. sept, vol.161, issue.3, pp.234-275, 2017.

M. Bene, G. Castoldi, W. Knapp, W. Ludwig, E. Matutes et al., Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leuk Off J Leuk Soc Am Leuk Res Fund UK, vol.9, pp.1783-1789, 1995.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood. 19 mai, vol.127, issue.20, pp.2391-405, 2016.

C. Pui, W. L. Carroll, S. Meshinchi, R. J. Arceci, and . Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update, J Clin Oncol. 10 févr, vol.29, issue.5, pp.551-65, 2011.

W. Crist, J. Pullen, J. Boyett, J. Falletta, J. Eys et al., Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group Study, Blood. 1 janv, vol.67, issue.1, pp.135-175, 1986.

H. N. Sather, Age at diagnosis in childhood acute lymphoblastic leukemia, Med Pediatr Oncol, vol.14, issue.3, pp.166-72, 1986.

R. R. Chilcote, P. Coccia, H. N. Sather, L. L. Robison, R. L. Baehner et al., Mediastinal mass in acute lymphoblastic leukemia, Med Pediatr Oncol, vol.12, issue.1, pp.9-16, 1984.

M. Smith, D. Arthur, B. Camitta, A. J. Carroll, W. Crist et al., Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia, J Clin Oncol Off J Am Soc Clin Oncol. janv, vol.14, issue.1, pp.18-24, 1996.

J. M. Goldberg, L. B. Silverman, D. E. Levy, V. K. Dalton, R. D. Gelber et al., Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience, J Clin Oncol Off J Am Soc Clin Oncol, vol.21, pp.3616-3638, 2003.

R. Consolini, A. Legitimo, R. Rondelli, C. Guguelmi, E. Barisone et al., Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica, vol.83, pp.967-73, 1998.

B. Gleissner, N. Goekbuget, H. Rieder, R. Arnold, S. Schwartz et al., CD10pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL), Blood. 15 déc, vol.106, issue.13, pp.4054-4060, 2005.

A. V. Moorman, New and emerging prognostic and predictive genetic biomarkers in Bcell precursor acute lymphoblastic leukemia, Haematologica. avr, vol.101, issue.4, pp.407-423, 2016.

L. Baranger, W. Cuccuini, C. Lefebvre, I. Luquet, C. Perot et al., Place de la cytogénétique dans la prise en charge des leucémies aiguës lymphoblastiques (LAL) de l'enfant et de l'adulte : actualisation par le Groupe francophone de cytogénétique hématologique (GFCH), Ann Biol Clin (Paris). 1 sept, vol.74, issue.5, pp.547-60, 2016.

A. Delannoy, John Libbey Eurotext-Hématologie-Leucémie lymphoblastique aiguë Philadelphie-positive, vol.12, pp.26-31, 2006.

J. Jaso, D. A. Thomas, K. Cunningham, J. L. Jorgensen, H. M. Kantarjian et al., Prognostic Significance of Immunophenotypic and Karyotypic Features of Philadelphia positive B-Lymphoblastic Leukemia in the Era of, Tyrosine Kinase Inhibitors. Cancer. 1 sept, vol.117, issue.17, pp.4009-4026, 2011.

A. Biondi, M. Schrappe, D. Lorenzo, P. Castor, A. Lucchini et al., Imatinib after induction for treatment of children and adolescents with Philadelphiachromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, openlabel, intergroup study, Lancet Oncol. sept, vol.13, issue.9, pp.936-981, 2012.

C. Meyer, J. Hofmann, T. Burmeister, D. Gröger, T. S. Park et al., The MLL recombinome of acute leukemias in 2013, Leukemia. nov, vol.27, issue.11, pp.2165-76, 2013.

C. Preudhomme, L. Llopis-c, and N. Boissel, Classification et facteurs pronostiques des leucémies aiguës. EM-Consulte

A. V. Moorman, S. M. Richards, H. M. Robinson, J. C. Strefford, B. Gibson et al., Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21), Blood. 15 mars, vol.109, issue.6, pp.2327-2357, 2007.

R. Marke, F. N. Van-leeuwen, and B. Scheijen, The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia, Haematologica. avr, vol.103, issue.4, pp.565-74, 2018.

K. G. Roberts, Y. Li, D. Payne-turner, R. C. Harvey, Y. Yang et al., Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia, N Engl J Med. 11 sept, vol.371, issue.11, pp.1005-1020, 2014.

K. G. Roberts, D. Pei, D. Campana, D. Payne-turner, Y. Li et al., Outcomes of Children With BCR-ABL1-Like Acute Lymphoblastic Leukemia Treated With RiskDirected Therapy Based on the Levels of Minimal Residual Disease, J Clin Oncol. 20 sept, vol.32, issue.27, pp.3012-3032, 2014.

A. V. Moorman, A. Enshaei, C. Schwab, R. Wade, L. Chilton et al., A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia, Blood. 28 août, vol.124, issue.9, pp.1434-1478, 2014.

U. Fischer, M. Forster, A. Rinaldi, T. Risch, S. Sungalee et al., Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options, Nat Genet. sept, vol.47, issue.9, pp.1020-1029, 2015.

N. Dastugue, S. Suciu, G. Plat, F. Speleman, H. Cavé et al., Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results, Blood. 28 mars, vol.121, issue.13, pp.2415-2438, 2013.

J. B. Nachman, N. A. Heerema, H. Sather, B. Camitta, E. Forestier et al., Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia, Blood. 15 août, vol.110, issue.4, pp.1112-1117, 2007.

M. Brüggemann, T. Raff, and M. Kneba, Has MRD monitoring superseded other prognostic factors in adult ALL? Blood, vol.120, pp.4470-81, 2012.

F. Ravandi, J. L. Jorgensen, S. M. O'brien, E. Jabbour, D. A. Thomas et al., Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia, Br J Haematol. févr, vol.172, issue.3, pp.392-400, 2016.

M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study, Blood. 15 juin, vol.111, issue.12, pp.5477-85, 2008.

W. Kern and S. Schnittger, Monitoring of acute myeloid leukemia by flow cytometry, Curr Oncol Rep. sept, vol.5, issue.5, pp.405-417, 2003.

E. Coustan-smith, J. Sancho, M. L. Hancock, J. M. Boyett, F. G. Behm et al., Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia, Blood, vol.96, issue.8, pp.2691-2697, 2000.

H. Cavé, J. Van-der-werff-ten-bosch, S. Suciu, C. Guidal, C. Waterkeyn et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group, N Engl J Med. 27 août, vol.339, issue.9, pp.591-599, 1998.

J. J. Van-dongen, T. Seriu, E. R. Panzer-grümayer, A. Biondi, M. J. Pongers-willemse et al., Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood, Lancet Lond Engl, vol.352, issue.9142, pp.1731-1739, 1998.

E. Coustan-smith, J. Sancho, M. L. Hancock, J. M. Boyett, F. G. Behm et al., Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia, Blood, vol.96, issue.8, pp.2691-2697, 2000.

C. Pui, P. D. Coustan-smith, E. Jeha, S. Cheng, C. Bowman et al., Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study, Lancet Oncol. avr, vol.16, issue.4, pp.465-74, 2015.

P. Bader, H. Kreyenberg, G. Henze, C. Eckert, M. Reising et al., Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group, J Clin Oncol Off J Am Soc Clin Oncol. 20 janv, vol.27, issue.3, pp.377-84, 2009.

P. Bader, J. Hancock, H. Kreyenberg, N. J. Goulden, D. Niethammer et al., Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL, Leukemia. sept, vol.16, issue.9, pp.1668-72, 2002.
DOI : 10.1038/sj.leu.2402552

URL : https://www.nature.com/articles/2402552.pdf

X. Ronot, D. Grunwald, . Mayol, and . Boutonnat, La Cytométrie en Flux. Lavoisier, 2006.

D. Vosková, L. Váleková, J. Fedorová, J. Hudecek, and P. Kubisz, Leukemic cells and aberrant phenotypes in acute leukemia patients: a flow cytometry analysis, Neoplasma, vol.50, issue.6, pp.422-429, 2003.

M. Béné and F. Lacombe, Place de la cytométrie en flux dans le diagnostic et le suivi des leucémies aiguës, Rev Francoph Lab. avr, vol.2015, issue.471, pp.35-41, 2015.

M. Roshal, J. R. Fromm, S. Winter, K. Dunsmore, and B. L. Wood, Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection, Cytometry B Clin Cytom. mai, vol.78, issue.3, pp.139-185, 2010.

D. Campana and . Leukemia, Hematol Oncol Clin North Am, vol.23, issue.5, pp.1083-98, 2009.

. Velden-vhj-van-der, G. Cazzaniga, A. Schrauder, J. Hancock, P. Bader et al., Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data, Leukemia. avr, vol.21, issue.4, pp.604-615, 2007.

A. Baruchel, J. M. Cayuela, E. Macintyre, R. Berger, and F. Sigaux, Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection, Br J Haematol. mai, vol.90, issue.1, pp.85-93, 1995.

M. Brüggemann, A. Schrauder, T. Raff, H. Pfeifer, M. Dworzak et al., Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, vol.24, pp.521-556, 2008.

J. S. Chen, E. Coustan-smith, T. Suzuki, G. A. Neale, K. Mihara et al., Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia, Blood. 1 avr, vol.97, issue.7, pp.2115-2135, 2001.

B. Drénou, O. Fardel, R. Fauchet, and L. Amiot, La cytométrie en flux : intérêt dans le diagnostic phénotypique et le suivi des hémopathies malignes, Ann Biol Clin, vol.60, issue.6, pp.663-72, 2002.

L. Mekkaoui, C. Rassart, L. Rozen, A. Janssens, D. Bron et al., Use of CD 123 Expression on Blasts from AML, ALL and RAEB As Minimal Residual Disease Marker, Blood. 3 déc, vol.126, issue.23, pp.5402-5402, 2015.

M. Veltroni, D. Zen, L. Sanzari, M. C. Maglia, O. Dworzak et al., Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia, Haematologica. nov, vol.88, issue.11, pp.1245-52, 2003.

R. Garand, K. Beldjord, H. Cavé, C. Fossat, I. Arnoux et al., Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia. févr, vol.27, issue.2, pp.370-376, 2013.

C. Fossat, M. Roussel, I. Arnoux, V. Asnafi, C. Brouzes et al., Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A french multicenter study: MRD Assessment by Flow Cytometry in All, Cytometry B Clin Cytom. janv, vol.88, issue.1, pp.21-30, 2015.

B. Denys, . Sluijs-gelling-aj-van-der, C. Homburg, C. E. Schoot, . Van-der et al., Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia, Leukemia. mars, vol.27, issue.3, pp.635-676, 2013.

. Velden-vhj-van-der, J. M. Wijkhuijs, J. Dongen, and . Van, Non-specific amplification of patient-specific Ig/TCR ge ne rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring, Leukemia. mars, vol.22, issue.3, pp.641-645, 2008.

C. Elie and I. Colombet, Methods of evaluation of reproducibility, Sang Thromb Vaiss. mars, issue.3, pp.138-145, 2011.

G. Gaipa, G. Cazzaniga, M. G. Valsecchi, R. Panzer-grümayer, B. Buldini et al., Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica, vol.97, pp.1582-93, 2012.

I. Thörn, E. Forestier, J. Botling, B. Thuresson, C. Wasslavik et al., Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry, Br J Haematol. 1 mars, vol.152, issue.6, pp.743-53, 2011.

J. Van-dongen, V. Van-der-velden, M. Brüggemann, and A. Orfao, Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies, Blood. 25 juin, vol.125, issue.26, pp.3996-4009, 2015.

S. P. Chantepie, E. Cornet, V. Salaün, and O. Reman, Hematogones: an overview, Leuk Res. nov, vol.37, issue.11, pp.1404-1415, 2013.

M. N. Dworzak, G. Gaipa, R. Ratei, M. Veltroni, A. Schumich et al., Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible, Cytometry B Clin Cytom, vol.74, issue.6, pp.331-371, 2008.

M. Ikoma, M. P. Beltrame, S. Ferreira, E. X. Souto, M. Malvezzi et al., Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia, Rev Bras Hematol E Hemoter, vol.37, issue.6, pp.406-419, 2015.

P. Theunissen, E. Mejstrikova, L. Sedek, A. J. Van-der-sluijs-gelling, G. Gaipa et al., Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia, Blood. 19 janv, vol.129, issue.3, pp.347-57, 2017.

T. Muzzafar, L. J. Medeiros, S. A. Wang, A. Brahmandam, D. A. Thomas et al., Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry, Am J Clin Pathol, vol.132, issue.5, pp.692-700, 2009.

C. Nagant, D. Casula, A. Janssens, V. Nguyen, and B. Cantinieaux, Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio, Int J Lab Hematol

N. Kiyokawa, K. Iijima, O. Tomita, M. Miharu, D. Hasegawa et al., Significance of CD66c expression in childhood acute lymphoblastic leukemia, Leuk Res. janv, vol.38, issue.1, pp.42-50, 2014.

T. Kalina, M. Vaskova, E. Mejstrikova, J. Madzo, J. Trka et al., Myeloid antigens in childhood lymphoblastic leukemia:clinical data point to regulation of CD66c distinct from other myeloid antigens, BMC Cancer. 12 avr, vol.5, p.38, 2005.

P. Qiu, Inferring phenotypic properties from single-cell characteristics, 2012.

. Disponible,

A. Marceau-renaut, A. Renneville, O. Nibourel, O. Jardin-mathé, C. Demay et al., Le séquençage de nouvelle génération (NGS) a-t-il déjà sa place dans nos laboratoires d'oncohématologie ?, Hématologie. 1 mars, vol.19, issue.2, pp.112-134, 2013.

C. Gawad, F. Pepin, V. Carlton, M. Klinger, A. C. Logan et al., Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia, Blood, vol.120, issue.22, pp.4407-4424, 2012.

S. Shin, I. S. Hwang, J. Kim, K. A. Lee, S. T. Lee et al., Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia, Ann Lab Med. juill, vol.37, issue.4, pp.331-336, 2017.

O. Sala-torra, M. Othus, D. W. Williamson, B. Wood, I. Kirsch et al., NextGeneration Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. avr, vol.23, issue.4, pp.691-697, 2017.

S. De-galien,

, Je jure d'honorer ceux qui m'ont instruit dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement

D. , intérêt de la Santé publique ma profession avec conscience et de respecter non seulement la législation en vigueur mais aussi les règles de l'Honneur

, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine

, De ne dévoiler à personne les secrets qui m'auraient été confiés ou dont j'aurais eu connaissance dans l'exercice de ma Profession

, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser les actes criminels

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses

, Que je sois méprisé de mes Confrères si je manque à mes engagements